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Aims Short QT syndrome (SQTS) is a genetically determined ion-channel disorder, which may cause malignant tachyar-
rhythmias and sudden cardiac death. Thus far, mutations in five different genes encoding potassium and calcium
channel subunits have been reported. We present, for the first time, a novel loss-of-function mutation coding for
an L-type calcium channel subunit.
Methods
and results
The electrocardiogram of the affected member of a single family revealed a QT interval of 317 ms (QTc 329 ms) with
tall, narrow, and symmetrical T-waves. Invasive electrophysiological testing showed short ventricular refractory
periods and increased vulnerability to induce ventricular fibrillation. DNA screening of the patient identified no
mutation in previously known SQTS genes; however, a new variant at a heterozygous state was identified in the
CACNA2D1 gene (nucleotide c.2264G. C; amino acid p.Ser755Thr), coding for the Cava2d-1 subunit of the L-
type calcium channel. The pathogenic role of the p.Ser755Thr variant of the CACNA2D1 gene was analysed by
using co-expression of the two other L-type calcium channel subunits, Cav1.2a1 and Cavb2b, in HEK-293 cells.
Barium currents (IBa) were recorded in these cells under voltage-clamp conditions using the whole-cell configuration.
Co-expression of the p.Ser755Thr Cava2d-1 subunit strongly reduced the IBa by more than 70% when compared with
the co-expression of the wild-type (WT) variant. Protein expression of the three subunits was verified by performing
western blots of total lysates and cell membrane fractions of HEK-293 cells. The p.Ser755Thr variant of the Cava2d-1
subunit was expressed at a similar level compared with the WT subunit in both fractions. Since the mutant Cava2d-1
subunit did not modify the expression of the pore-forming subunit of the L-type calcium channel, Cav1.2a1, it
suggests that single channel biophysical properties of the L-type channel are altered by this variant.
Conclusion In the present study, we report the first pathogenic mutation in the CACNA2D1 gene in humans, which causes a new
variant of SQTS. It remains to be determined whether mutations in this gene lead to other manifestations of the J-
wave syndrome.
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Introduction
Short QT syndrome (SQTS) is a genetically determined
ion-channel disorder, which may cause malignant tachyarrhythmias
and sudden cardiac death (SCD). The definition of the short QT
interval varies in the literature1–5 but is generally defined as a
QTc interval below 330 ms.6,7 The diagnosis of SQTS can be
made in patients with a short QTc interval who present with
additional clinical findings, such as syncope, episodes of poly-
morphic ventricular tachycardia or ventricular fibrillation, or a
family history of unexplained SCD. The disease usually affects
young and healthy individuals who have no underlying structural
heart disease.2 To date, five genes have been identified that are
responsible for SQTS, demonstrating a genetically heterogeneous
disease (Table 1).5,7 –9 Short QT syndrome 1, SQTS2 and SQTS3
are caused by gain-of-function mutations of cardiac potassium
channels causing hastened repolarization.5,8,9 Short QT syndrome
1 is due to mutations in KCNH2 encoding the a-subunit of the
HERG IKr channel, which lead to heterogeneous shortening of
the action potentials and refractoriness.9 Typically, on surface elec-
trocardiogram (ECG), the ST-segment is absent and the T-wave is
tall, narrow, and symmetrical. The triggering factors are usually
adrenergic-dependent; however, some cases at rest have also
been described.10 Short QT syndrome 2 is associated with
mutations in KCNQ1 encoding the a-subunit of the KvLQT1 IKs
channel.8 Short QT syndrome 3, which is caused by a mutation
in KCNJ2 is characterized by nocturnal palpitations.5 In contrast
to SQTS1, SQTS2, and SQTS3, loss-of-function missense
mutations in CACNA1C and CACNB2 genes, which are subunits of
the cardiac L-type calcium channel, have been identified in
SQTS4 and SQTS5.7 The latter two subtypes are associated with
asymmetrical T-waves, attenuated QT-heart rate relations, and
the presence of atrial fibrillation. These patients may also
present with a Brugada-like surface ECG pattern with or without
drug provocation.7 Loss-of-function mutations in the potassium
channels have also been reported for the long QT1, long QT2,
and the Andersen–Tawil syndrome (long QT7).11–13
Recent studies have shown that inherited cardiac arrhythmias
may be caused by mutations found in the genes coding for the
subunits of the L-type Ca channel.7,14 In cardiac myocytes,
Cav1.2 channels are predominant. Cav1.2 channels are formed of
a pore-forming Cav1.2a1 subunit (CACNA1C gene), which carries
the main biophysical and pharmacological properties of the chan-
nels, and accessory subunits Cavb2b (CACNB2b gene) and
Cava2d-1 (CACNA2D1 gene). Cavb and Cava2d subunits play a
dual role in regulating both the biophysical properties and traffick-
ing of Cav channels.
15,16 Cavg subunits are also expressed in
cardiac myocytes; however, there is no evidence that they interact
with cardiac Cav1.2 channels.
17
In this study, mutation analysis was performed for all genes,
which have been identified to be linked to SQTS (KCNH2,
KCNQ1, KCNJ2, CACNA1C, and CACNB2b) and in those that are
considered to be candidate genes for SQTS (CACNA2D1, KCNJ8,
and Sur2A).7,14 We report a new variant of SQTS caused by a
mutation in the gene encoding the Cava2d-1 subunit of the
L-type calcium channel (CACNA2D1).
Methods
Molecular genetic analysis
Genomic DNA from the index patient was extracted from peripheral
blood leucocytes using a commercial kit (Gentra System, Puregene,
Valencia, CA, USA). All exons and intron borders of cardiac ion
channel genes including but not limited to all isoforms of KCNQ1,
KCNH2, SUR2A, KCNJ8, KCNJ2, CACNA1C, CACNB2b, and CACNA2D1
geneswere amplified and analysed by direct sequencing from both direc-
tions using an ABI PRISM 3100-Avant Automatic DNA sequencer
(Applied Biosystems, Foster City, CA, USA). Genomic DNA from 410
reference alleles from healthy ethnically matched controls from the
USA and 402 ethnically matched healthy reference alleles from southern
Germany were used as controls. The CACNA2D1 primers used for
screening are shown in Table 2. Family screening of the c.2264G. C
(p.Ser755Thr) mutation in CACNA2D1 was performed according to
standard protocols after exon amplification by polymerase chain reac-
tion (PCR) with the intronic primers: forward 5′-GGGGGAGAGCA
GATAGTAGC-3′ and reverse 5′-GCTATGCTGATGCATTGCT-3′ .
The 352 bp PCR products were directly sequenced on both strands in
the family and on one strand in the controls using an ABI 3730 capillary
sequencer. The reference sequence was based on ENSE00002087663.
Written informed consent was obtained from all family members
prior to the genetic study.
cDNA constructs
Rabbit Cav1.2a1 (cP15381.1), Cavb2b (P54288), and Cava2d-1
(P13806) cDNAs, inserted into pCARDHE, pBH17, and pCA1S,
respectively, were gifts from Dr G.S. Pitt (Division of Cardiology,
Department of Medicine, Duke University Medical Center, Durham,
NC, USA). CD8 cDNAs subcloned into EBOpcD-Leu2 [American
Type Culture Collection (ATCC), Rockville, MD, USA]. CACNA2D1
mutation was engineered into wild-type (WT) cDNA using the Quick-
Change Kit (Stratagene, USA) and verified by sequencing.
Transfections
For electrophysiology experiments, HEK-293 cells were transiently
transfected using the calcium phosphate method and 0.3 mg cDNAs
of each Cav channel subunit (Cav1.2a1, Cavb2b, and Cava2d-1; ratio
1:1:1) together with 1.0 mg of empty pcDNA3.1 vector. In addition,
0.5 mg of cDNA encoding CD8 antigen was added to all transfections
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Update of the currently known genes causing
short QT syndrome and their mutations
SQTS
type
Gene
symbol
Ionic
current
Effect of
mutation on
channel
function
Reference
SQTS1 KCNH2 IKr  Brugada et al.9
SQTS2 KCNQ1 IKs  Bellocq et al.8
SQTS3 KCNJ2 IK1  Priori et al.5
SQTS4 CACNA1C ICa  Antzelevitch
et al.7
SQTS5 CACNB2b ICa  Antzelevitch
et al.7
IKr, rectifier K
+ current rapid component; IKs, rectifier K
+ current slow
component; IK1, inward rectifier K
+ current; ICa, Ca
2+ current.
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as a reporter gene. At 24 h post-transfection, cells were split at low
density (3% of one 25 cm2 flask per dish). Anti-CD8 beads (Dynalw,
Oslo, Norway) were used to identify transfected cells. For biochemis-
try experiments, 10 cm dishes of HEK-293 cells were transfected using
lipofectamine LTXw (Invitrogen, Basel, Switzerland) according to the
manufacturer’s instructions. Cells were used 48 h after transfection.
The ratio cDNAs/lipofectamine was 7.5 mg cDNAs/30 mL Lipofecta-
mine. The ratio of the different constructs was similar to those used
in patch-clamp experiments.16
Electrophysiology
Whole-cell currents were measured at room temperature (22–238C)
using a VE-2 amplifier (Alembic Instrument, USA). The internal pipette
solution was composed of (in mmol/L) 60 CsCl, 70 Cs-aspartate, 1
MgCl2, 10 HEPES, 11 EGTA, and 5 Mg-ATP, pH 7.2, with CsOH.
The external solution contained (in mmol/L) 130 NaCl, 5.6 KCl, 5
BaCl2, 1 MgCl2, 10 HEPES, and 11 D-glucose, pH 7.4, with NaOH.
Data were analysed using pClamp software, version 10.2 (Axon Instru-
ments, Union City, CA, USA). Barium current densities (pA/pF) were
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Primers of CACNA2D1 gene
CACNA2D1 gene segment Primers sequence (5′  3′)
Exon Sense Anti-sense
1 5′-GTGTGCTGCTCTTCCTCCG-3′ 5′-CGCGACTCGGGAACCGAC-3′
2 5′-GACATAGTCGGTGCTAGGAG-3′ 5′-GTTCACAGTACCTAGCAGTAC-3′
3 5′-CAGGGTGGTGTTTCTAATCAG-3′ 5′-GATGAACACAGTTACTAAGAAG-3′
4 5′-CTGATGATGGCAGAGGTAAC-3′ 5′-GGCTAACTTAATTGGCCCTG-3′
5 5′-CAATGCAAGATGTAATATCACTG-3′ 5′-CTCATGCAGTCTAACATTGTC-3′
6 5′-GTGAGTGCTAATACCTGAATG-3′ 5′-CATGGATGCAGGCTGTCCT-3′
7 5′-GATCCAGTCAAACTGTCCTC-3′ 5′-CAGTTTAAAGTGACTGTGGTC-3′
8 5′-GAACATTGAAGTACGTAAGTGA-3′ 5′-CATTACCCACTTGAACTCATC-3′
9 5′-CATTGTCTACTTAGATAGAAGTG-3′ 5′-GTCTTGATATGGCTTCATTGC-3′
10 5′-GTACACATACTGATATTGGGAG-3′ 5′-CAGGTCAGTAAGATAGTCTTG-3′
11 5′-GAGTAAGCAATGCAATACCGT-3′ 5′-CTTCTGCCTGCACACATCTG-3′
12 5′-GATCCAGGAACCAGTTCTTAG-3′ 5′-GCATGAGTTGCTTGTGAATATG-3′
13 5′-CTGAAGGCTTTACTGGCCTC-3′ 5′-CATGTTCAGAATCTTACTCTTG-3′
14 5′-GCCTGTGTGTTTGTTGTGAAG-3′ 5′-CAATGTATCAACAAGATACTCAG-3′
15 5′-CCATACCACCTATGGAGTAC-3′ 5′-CAATGAAGGGATCAAGTAGAC-3′
16 5′-CTTCAGTAGGTGCCTAGTAG-3′ 5′-GTGGTTATCGCATAGGCAGC-3′
17 5′-GACACTGAGAGTGCTTCACC-3′ 5′-GTTCCTTTGCTAAGATAACTG-3′
18 5′-CTTGGCACTTAGGTAATTCTC-3′ 5′-GTTGCAGCTAAATTGGTAACAG-3′
19 5′-GCAGTATCAAATACAGCACTC-3′ 5′-CCGTTCAACAGATACTTGTAG-3′
20 5′-GAGAACAACTACAGATACTGG-3′ 5′-CATCAAGAAACCTAAAGCAATAG-3′
21 5′-GATCATACCTTTGTAAAGATGAG-3′ 5′-CATGTTGGGAACTTTTCTAGTG-3′
22 5′-GACTCTGGATGGCAAGACTG-3′ 5′-CCTGCTCATATTCTATCCATG-3′
23 5′-CCTCAGACTACAGCTGTAC-3′ 5′-CTAAGTTTTGAGTGATCAAG-3′
24 5′-GTACCATGTTATGAAGTTATCC-3′ 5′-GATTCCATAATGTGATATGAAAC-3′
25 5′-GAAGTAACAAGAAGCTCAATAG-3′ 5′-CGTATCCTATGATATACTATAACC-3′
26 5′-CTACTAAATCCATTCATTTCCTG-3′ 5′-GTAATAGCAGACATTAGTACT-3′
27 5′-GAGATGTCTTCCTTAAACATCC-3′ 5′-CAATGTAATCTAATGGCAATCAG-3′
28 5′-CTGATGCATTGCTCAGTAATG-3′ 5′-CTGATGCATTGCTCAGTAATG-3′
29 5′-CAGTTAGCCTAGTGTATACAAC-3′ 5′-CAACTTCAGAGGTAACTAGTC-3′
30 5′-CAGGTTGTGGCTAATGAATAC-3′ 5′-GAATTCTACTTCAGTGTAGTGG-3′
31 5′-CAAGGTTATAACATGCAATGCT-3′ 5′-CAGTTGAGACCGAAGAGAAC-3′
32 5′-CATGTATATAATGGGGTAAAGAC-3′ 5′-CTTAGCATGCATTTCTTAATGG-3′
33 5′-GCTCCTCAGTTGTACTTCAG-3′ 5′-GTAATATGTCTGCTACTGATGG-3′
34 5′-GACATCGCTCAGCATATGTG-3′ 5′-GGAAGACTCTAAAGAGGCTG-3′
35 5′-CACTTGACTCTGAACAAGATC-3′ 5′-CAAGATGGCTATGAGATCAGG-3′
36 5′-CACAGTAGTAAACAAGCCAG-3′ 5′-CTCACATCTCTGACTCCAAC-3′
37 5′-CTCCTATTGTGCTGGGAATG-3′ 5′-CGAGGTGATCAGAGCAGTC-3′
38 5′-GTGTTGGATGAGAGTAATGATG-3′ 5′-GAAGCAACTGTCAAGTTTATGC-3′
39 5′-GCATTTGTCAAATGATGCTAGG-3′ 5′-GACATGCAGCCAGTGGGTG-3′
Novel loss-of-function calcium channel gene mutation in SQTS 1079
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calculated dividing the peak current by the cell capacitance. Activation
curves and steady-state inactivation curves were fitted with the follow-
ing single Boltzmann’s equation: y ¼ 1/{1 + exp[(Vh–V50)/k]}, in which
y is the normalized conductance or peak current at a given holding
potential (Vh), V50 the voltage at which half of the channels are acti-
vated (V50,act) or inactivated (V50,inact), respectively, and k the slope
factor.
Western blots
Ten centimetre HEK-293 cell dishes were lysed in 1.0 mL of lysis buffer
(50 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 10% glycerol, 1%
Triton, and 1 mmol/L EGTA supplemented with protease inhibitors).
Protein concentration was systematically determined by performing
a Bradford assay (Coo protein dosage kit; Interchim, Montluc¸on,
France). Seventy micrograms of proteins were loaded on SDS–
Figure 1 Twelve-lead electrocardiogram of the patient with short QT syndrome. (A) QT interval is 317 ms (QTc 329 ms) on resting surface
electrocardiogram at presentation (paper speed 25 mm/s). (B) Surface electrocardiogram prior to and after flecainide challenge test. (1)
Twelve-lead electrocardiogram shows incomplete right bundle branch block at baseline. (2) Ten minutes after flecainide (2 mg/kg) adminis-
tration, a prominent notch in V1 in the early ST-segment (arrow) is depicted. Notably, the ST-segment becomes more convex. (3) Fifteen mi-
nutes after flecainide challenge, reduction in the QRS amplitude in V1 is observed. (4) Twenty minutes later, a prominent Q-wave is seen in V1.
Six hours later, the right precordial electrocardiogram changes returned to baseline.
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PAGE gel. Protein transfer was done with the dry system transfer
i-blotw from Invitrogen. Immunoblotting was done using the
snap-idw system of Millipore (Zug, Switzerland). Fluorescent second-
ary antibodies at dilution 1/10 000 were used and detection was rea-
lized using the LICOR systemw (Lincoln, NE, USA).
Cell membrane biotinylation
Cells were treated for 30 min at 48C with 4 mL biotin per 10 cm dish
(1 mg/mL; EZ link Sulfo-NHS-SS-Biotin; Pierce, Rockford, IL, USA),
washed three times with cold PBS 1× containing 200 mmol/L
glycine and lysed with 1 mL/dish of lysis buffer. Fifty microlitres of
streptavidin sepharose beads (GE Healthcare Europe, Glattbrugg, Swit-
zerland) were added to 1 mg of HEK-293 cell lysate and incubated 2 h
on a wheel at 48C. The beads were washed five times with lysis buffer
and resuspended in sample buffer (Invitrogen). Eluted proteins were
analysed by western blot.
Antibodies
Antibodies against Cav1.2a1 (ACC003) (Alomone, Jerusalem, Israel),
Cavb2b (ab54920), and Cava2d-1 (ab2864) (Abcam, Cambridge, UK)
were used at a dilution of 1/200 for Cav1.2a1 and Cavb2b and
1/1000 for Cava2d-1. Monoclonal antibodies raised against actin
were purchased from Sigma-Aldrich (Sigma-Aldrich Chemie, Buchs,
Switzerland) and used at a dilution of 1/1000.
Computational analysis of the p.Ser755Thr
mutation in CACNA2D1
The domain architecture of CACNA2D1 was deduced from the BioIn-
foBank MetaServer.18 Transmembrane regions were identified using
Memsat 3.19,20 The structure of the sensory domain of CACNA2D1
was modelled with Modeler 6.2 using the crystal structure of Histidine
Kinase Dctb Sensor Domain as a template (PDB code 3by9). The
Ser755Thr mutation was generated using Sybyl 7.3 (Tripos Inc.), and
DS Visualizer v2.5 (Accelrys Inc.) was used for structure analysis and
visualization.
Statistical analysis
Data are presented as means+ SEM. Unpaired, two-tailed Student’s
t-test was used to compare the means; P, 0.05 was considered
significant.
Results
Clinical case
An otherwise healthy, 17-year-old female of Caucasian origin had a
sudden loss of consciousness while sitting during a church service.
Basic life support was administered immediately and the initial
rhythm recorded ventricular fibrillation which was successfully ter-
minated in a stable sinus rhythm after two external defibrillation
shocks. The patient was subsequently transferred to a hospital
by emergency medical personnel. The ECG revealed a QT interval
of 317 ms (QTc 329 ms) with tall, narrow, and symmetrical
T-waves, suggestive of SQTS (Figure 1A). Transthoracic echocar-
diography excluded any structural heart disease and coronary
angiography showed normal coronary arteries. Invasive electro-
physiological testing revealed AH and HV intervals within the
normal range; the atrial effective refractory period was 180 ms
and AV block cycle length was 420 ms. There was an AH jump
of 70 ms, suggesting the presence of a slow pathway. Programmed
stimulation from the high right atrium induced a non-sustained
atrial tachycardia originating from the posterior left atrium, as
well as atrial fibrillation, which terminated spontaneously. Pro-
grammed stimulation from the right ventricular apex with S1/S2
of 600/260 ms could induce a polymorphic ventricular tachycardia
Figure 2 Genetic analysis identified a novel CACNA2D1 mutation. (A) Electropherograms of wild-type (WT) and mutant CACNA2D1 gene
showing a heterozygous transition c.2264G. C predicting replacement of serine by threonine at position 755 (p.Ser755Thr). (B) Amino
acid sequence alignment showing that serine at position 755 is highly conserved among mammalian species. (C) Predicted topology of the
L-type calcium channel Cava2d-1 subunit showing the location of the S755T mutation (red circle) at the external carboxyl terminal of
CACNA2D1. AID, a-subunit-interacting domain. BID, b-subunit-interacting domain.
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degenerating into ventricular fibrillation, which was terminated
externally. An incomplete right bundle branch block was observed
intermittently. Flecainide provocation (2 mg/kg) did not reveal a
typical Brugada ECG pattern, despite placement of the right pre-
cordial leads in a superior position. However, distinct
repolarization changes in V1 were observed (Figure 1B). The
patient was treated with a b-blocker (nebivolol, 5 mg q.d.) and
she underwent implantation of a single-chamber implantable
cardioverter defibrillator (ICD). At 24-month follow-up, the
patient has not reported any symptomatic arrhythmias and the
Figure 3 (A) Pedigree of the reported family. (B) Right precordial electrocardiographic leads (V1, V2, and V3; 25 mm/s; electrodes were
placed in the normal position) and the QTc intervals of the family members. Paternal grandmother had a previous anteroseptal myocardial
infarction and paternal grandfather had an implanted pacemaker. The black arrows mark the index patient.
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ICD registered only one episode of a non-sustained ventricular
tachycardia (five beats with a cycle length of 250 ms).
Molecular genetics analysis
Screening of the genomic DNA of the patient has identified no
mutations in previously known SQTS genes, i.e. KCNH2, KCNQ1,
KCNJ2, CACNA1C, and CACNB2b. In addition, no mutations in
KCNJ8 and SUR2 have been detected. A novel heterozygous
mutation consisting of a G-to-C transition at nucleotide 2264
(c.2264 G. C) in CACNA2D1 predicting a substitution of a threo-
nine for serine at residue 755 (p.Ser755Thr) of CACNA2D1
(Cava2d-1) subunit of the cardiac L-type calcium channel
(Ser755Thr) was found (Figure 2A). The mutation was not found
in 812 reference alleles from healthy ethnically matched controls.
Alignment of the amino acid sequence of Cava2d-1 indicates that
serine at position 755 is highly conserved among species
(Figure 2B). Residue Ser755 is located at the external carboxyl
terminal region of Cava2 (Figure 2C).
Family screening showed that the father who had borderline
QTc interval and the paternal grandmother were also carriers of
this variant (Figure 3). Both mutation carriers were asymptomatic
regarding syncope, seizures, or arrhythmic events. In addition, no
prior SCD event or arrhythmia has occurred in this family
before. Baseline ECG of both family members did not display a
Brugada syndrome (BrS) pattern. Electrophysiological and drug
challenge testing to the affected family members was rec-
ommended; however, this was declined.
Functional analyses
In order to determine a possible pathogenic role of the
p.Ser755Thr variant in the CACNA2D1 gene, in vitro analyses
were performed using co-expression of the two other L-type
calcium channel subunits, Cav1.2a1 and Cavb2b, in HEK-293
cells. First, protein expression of the three subunits was verified
by performing western blots of total lysates of HEK-293 cells.
The p.Ser755Thr variant of the Cava2d-1 subunit was expressed
at a similar level compared with the WT subunit (Figure 4A). In
addition, this variant did not modify the expression of the pore-
forming subunit of the L-type Ca channel, Cav1.2a1. Secondly,
barium currents (IBa) were recorded in these cells under voltage-
clamp conditions using the whole-cell configuration.
Co-expression of the p.Ser755Thr Cava2d-1 subunit strongly
reduced IBa by more than 70% when compared with the
co-expression of the WT variant (Figure 4B and C, and Table 3).
Small positive shifts of the inactivation and activation curves
were observed when the mutant Cava2d-1 subunit was expressed
(Figure 4D). These alterations of the biophysical properties of the
current are similar to the condition in which the L-type channel
is expressed without the Cava2d subunit (Figure 4E and F, and
Table 3). Then, in order to understand the mechanisms underlying
the strong reduction in IBa caused by the co-expression of
Cava2d-1 p.Ser755Thr, we analysed the expression of Cav1.2a1
and Cava2d-1 subunits at the cell surface by performing membrane
protein biotinylation assays. As shown in Figure 5, the mutant
variant of the Cava2d-1 subunit was equally well expressed at
the cell surface when compared with the WT control. A similar
result was obtained for the Cav1.2a1. Altogether these results
suggest that the mutation p.Ser755Thr of Cava2d-1 alters some
of the single channel biophysical properties of the L-type channel
at the cell membrane.
Computational analyses
CACNA2D1 is predicted to be anchored in the cellular membrane
by a carboxy-terminal transmembrane helix (residues 1067–1087).
The largest part of the protein, including the site of the
p.Ser755Thr mutation, is located in the extracellular space. A com-
putational analysis based on sequence and structure similarities
suggests that the mutation is located in a sensory domain (residues
659–889) whose exact physiological function is not known to
date. Molecular modelling of this domain reveals that Ser755 is
located at a sterically demanding position and is oriented
towards the interior of a protein (Figure 6A). In the WT protein,
Ser755 tightly packs against a valine (Val799) of the opposite
b-strand (Figure 6B). The additional methyl group present in
Thr755 of the mutant protein cannot be accommodated in the
core of the protein and leads to clashes with the side chain of
Val799 (Figure 6C). These clashes may potentially alter some of
the, yet unknown, functions of this protein.
Discussion
In the present study, we report a variant in the CACNA2D1 gene
(c.2264G. C; p.Ser755Thr), which, on the basis of our functional
studies, is most likely pathogenic. Mutations in CACNA2D1 hence
cause a new variant of SQTS. This gene has been recently pro-
posed to be linked to BrS and early repolarization syndrome;21
however, the pathogenicity of the found variants has, thus far,
not been demonstrated. In the present report, the patient who
presented with survived SCD in the absence of structural heart
disease presented a short QTc interval at baseline and repolariza-
tion abnormalities in the right precordial leads during flecainide
challenge. Invasive electrophysiological testing in this patient
showed short atrial refractory periods and induction of non-
sustained atrial tachycardia and atrial fibrillation during pro-
grammed stimulation in the atrium and polymorphic ventricular
tachycardia and ventricular fibrillation during programmed stimu-
lation in the ventricle. The CACNA2D1 mutation most likely plays
a role in the occurrence of these electrophysiological findings
and in the observed intermittent incomplete right bundle branch
block. Repolarization abnormalities that may be suggestive of BrS
were neither present at rest nor during flecainide provocation
test. Likewise, the patient did not show an early repolarization
pattern on numerous baseline and follow-up ECGs as well as
during drug challenge. Recently, BrS and early repolarization syn-
drome, both associated with J-wave abnormalities, were proposed
to represent different manifestations of a ‘J-wave syndrome’.22
Although the genetic origin of early repolarization syndrome is
still unknown, mutations in a and b calcium channel subunits
lead to a clinical phenotype very close to BrS.7,14 Hence, based
on the observation that the Cava2d-1 subunit mutation lead to a
decreased calcium current (similarly to the a and b mutations)
and that a peculiar alteration of the J-wave was observed upon fle-
cainide challenge, it may be suggested that these clinical manifes-
tations including a prominent shortening of the QT interval are
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also part of a continuum caused by decreased calcium current. It
remains to be seen whether, in the future, more patients with
similar phenotypes caused by mutations in calcium channel genes
will permit a better definition of this J-wave syndrome.
Genetic analyses revealed that both father and paternal grand-
mother were heterozygous carriers of the missense mutation
p.Ser755Thr in CACNA2D1. However, both carriers failed to
display any ECG alteration compatible with SQTS. This obser-
vation is in line with the fact that penetrance and expressivity
in patients with SQTS are known to be very variable, ranging
from asymptomatic carriers to symptomatic patients with
atrial-, ventricular fibrillation, and SCD.23 Compared with the
congenital long QT syndrome 1–3, robust genotype–phenotype
correlations are still lacking for SQTS. This is the reason why
Brugada et al.24 have proposed that management must still rely
on clinical findings.
The mutation that has been found in the CACNA2D1 gene affects
the L-type calcium channel, which is responsible for the cardiac
Figure 4 The barium current (IBa) is reduced by Cava2d-1 p.Ser755Thr. (A) Western blot showing that the expression of all subunits is not
modified in the condition where Cava2d-1 p.Ser755Thr is expressed compared with the control condition (Cav1.2a1/Cavb2b/Cava2d-1). (B)
Representative whole-cell current traces at 0 mV during 200 ms. (C) I–V relationships recorded (protocol in inset) from HEK-293 cells trans-
fected with Cav1.2a1/Cavb2b/Cava2d-1 channels (open circle) or with Cav1.2a1/Cavb2b/Cava2d-1 p.Ser755Thr (filled circle). (D) Activation
curves and steady-state inactivation curves recorded (protocol in inset) from HEK-293 cells transfected under the same condition of transfec-
tion as in (C) and fitted as mentioned in the Methods section. Activation curves: Cav1.2a1/Cavb2b/Cava2d-1 (open circle)
V1/2¼ 210.5+0.6 mV, K ¼ 5.9+0.4; Cav1.2a1/Cavb2b/Cava2d-1 p.Ser755Thr (filled circle) V1/2 ¼ 28.4+ 0.9 mV (*compared with
Cav1.2a1/Cavb2b/Cava2d-1), K ¼ 6.1+ 0.3 (n.s. compared with Cav1.2a1/Cavb2b/Cava2d-1). Steady-state inactivation curves: Cav1.2a1/
Cavb2b/Cava2d-1 (open diamond) V1/2 ¼ 233.1+0.9 mV, K ¼ 7.9+ 0.3; Cav1.2a1/Cavb2b/Cava2d-1 p.Ser755Thr (filled diamond)
V1/2 ¼ 230.6+0.5 mV (**compared with Cav1.2a1/Cavb2b/Cava2d-1), K ¼ 8.2+0.5 (n.s. compared with Cav1.2a1/Cavb2b/Cava2d-1). (E)
I–V relationships recorded (protocol in inset) from HEK-293 cells transfected with Cav1.2a1/Cavb2b/Cava2d-1 channels (open circle) or
with Cav1.2a1/Cavb2b (filled circle). (F) Activation curves and steady-state inactivation curves recorded (protocol in inset) from HEK-293
cells transfected in the same condition as in (E) and fitted as mentioned in the Methods section. Activation curves: Cav1.2a1/Cavb2b/
Cava2d-1 (open circle) V1/2 ¼ 210.5+ 0.6 mV, K ¼ 5.9+0.4; Cav1.2a1/Cavb2b (filled circle) V1/2 ¼ 22.0+0.6 mV (***compared
with Cav1.2a1/Cavb2b/Cava2d-1), K ¼ 7.6+ 0.3 (**compared with Cav1.2a1/Cavb2b/Cava2d-1). Steady-state inactivation curves: Cav1.2a1/
Cavb2b/Cava2d-1 (open diamond) V1/2 ¼ 233.1+ 0.9 mV, K ¼ 7.9+0.3; Cav1.2a1/Cavb2b (filled diamond) V1/2 ¼ 226.0+2.8 mV
(*compared with Cav1.2a1/Cavb2b/Cava2d-1), K ¼ 12.4+ 1.3 (**compared with Cav1.2a1/Cavb2b/Cava2d-1). The number of cells recorded
is indicated in parentheses. *P, 0.05, **P, 0.01, and ***P, 0.001.
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Figure 4 Continued.
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Table 3 Effect of Cava2d-1 wild-type and Cava2d-1 p.Ser755Thr on Cav voltage dependence of activation and
steady-state inactivation
Cav1.2a1/Cavb2b Cav1.2a1/Cavb2b/Cava2d-1 Cav1.2a1/Cavb2b/Cava2d-1
p.Ser755Thr
Activation
V50,act (mV) 22.0+0.6 (7)*** 210.5+0.6 (13)
# 28.4+0.9 (6)
k (mV) 7.6+0.3 (7)** 5.9+0.4 (13) n.s. 6.1+0.3 (6)
Steady-state inactivation
V50,inact (mV) 226.0+2.8 (7) n.s. 233.1+0.9 (13)
## 230.6+0.5 (6)
k (mV) 12.4+1.3 (7)** 7.9+0.3 (13) n.s. 8.2+0.5 (6)
Current density (pA/pF)
Peak (pA/pF and %) 17+3 (10) n.s. 56+9 (20)### 13+4 (8)
30+5% n.s. 100+16%### 23+7%
Cav1.2a1/Cavb2b channels were expressed without Cava2d with Cava2d-1 wild-type or Cava2d-1 p.Ser755Thr. V50 values indicates the respective voltage at which 50% of the
channels are activated (V50,act) or inactivated (V50,inact), and k the slopes of the corresponding Boltzmann-fitted curves described in the Methods section. Amplitude of current is
expressed in current densities and percentage of variation (%) from the controls (Cav1.2a1/Cavb2b/Cava2d-1; 100%). Values are means+ SEM. The number of cells is indicated in
parentheses. n.s., not significant compared with Cav1.2a1/Cavb2b/Cava2d-1 p.Ser755Thr condition.
**P, 0.01.
***P, 0.001.
#P, 0.05.
##P, 0.01.
###P, 0.001.
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action potential plateau phase and the cytoplasmic Ca2+ transients
regulating the contraction force.25,26 The auxiliary Cava2d-1
subunit is known to be involved in the forward trafficking, mem-
brane turnover, and modulation of biophysical properties of the
pore-forming Cava1 subunits.
27 The molecular mechanisms under-
lying these effects are however only poorly understood. Until now,
no demonstrated pathogenic variants in the Cava2d-1 subunit have
been associated with SQTS. The variant carried by the patient is
most likely the cause of the SQTS phenotype since it strongly
reduces the Cava1-mediated current in the used cellular
expression system. The fact that the cellular protein expression
of the three expressed subunits in the cell lysates and of the
Cava1 at the cell membrane was not found to be modified by
the mutant Cava2d-1 subunit suggests that this variant alters
some of the biophysical single channel properties of channel at
the membrane. Further experiments are needed to understand
this intriguing finding.
Interestingly, it has been shown that loss-of-function mutations
in CACNA1C, the gene encoding the pore-forming subunit of the
cardiac Ca2+ current, contribute to SQTS type 4, whereas
gain-of-function mutations produce non-inactivating Ca2+ currents
and prolonged action potentials leading to a prolonged QT interval
on the ECG defined as the Timothy syndrome or congenital long
QT syndrome type 8.28,29 Similarly, gain- or loss-of-function
mutations found in the genes coding for Na+ or K+ channels
were found to be responsible for either long QT and BrS pheno-
types. It may therefore be speculated that gain- or loss-of-function
mutations in the CACNA2D1 gene could also lead to different
arrhythmogenic phenotypes. On the basis of the results of the
present study and the recent work of Burashnikov et al.,14 BrS
and SQTS may be allelic disorders caused by loss-of-function
mutations in CACNA2D1. Obviously, further work is needed to
understand the detailed mechanisms underlying the molecular
mechanisms of these clinical entities.
Figure 5 Surface biotinylation assays were performed using Cav1.2a1/Cavb2b/Cava2d-1 and Cav1.2a1/Cavb2b/Cava2d-1 p.Ser755Thr subunit-
transfected HEK-293 cells. (A) Western blots showing Cav1.2a1 and Cava2d-1 subunits detected in the whole-cell lysates and (C) correspond-
ing biotinylated fraction. (B and D) Bar graphs summarizing the effect of the mutation on the expression of Cav1.2a1 and Cava2d-1 subunits in
whole-cell lysates (B) and in biotinylated fractions (D). The number of independent experiments is indicated in parentheses; n.s., not significant
compared with control cells transfected with Cav1.2a1/Cavb2b/Cava2d-1 subunits.
C. Templin et al.1086
 at U
niversität Zürich. H
auptbibliothek Irchel on D
ecem
ber 11, 2011
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
In summary, this study identifies for the first time a pathogenic
variant in the CACNA2D1 gene, encoding the Cava2d-1 subunit of
the L-type calcium channel, as cause of SQTS, hence defining
SQTS6. These findings underline the crucial role of the different
subunits of the cardiac L-type calcium channel in inherited channe-
lopathies in general, and in SQTS in particular. Whether mutations
in CACNA2D1 may cause other manifestations of J-wave syn-
drome22 remains to be investigated.
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